Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Zealand Pharma Announces Preliminary H2 2022 Revenue $6.1M

Author: Benzinga Newsdesk | August 11, 2022 09:02am

Financial results for the first half of 2022

Revenue: DKK 43.5 million / USD 6.1 million (DKK 42.3 million / USD 6.8 million in the first six months of 2021).
Net operating expenses: DKK -502.6 million / USD -70.2 million (DKK -582.4 million / USD -93.1 million in the first six months of 2021).
Net operating result: DKK -539.2 million / USD -75.3 million (DKK -551.9 million / USD -88.2 million in the first six months of 2021).
Net financial items: DKK -61.8 million / USD -8.6 million (DKK 5.5 million / USD 0.9 million in the first six months of 2021).
Net result from Discontinued Operations Related to Restructuring: DKK -97.9 million / USD -13.7 million (DKK 0.6 million / USD 0.1 million in the first six months of 2021).
- Cash, cash equivalents, and marketable securities: DKK 864.4 million / USD 120.7 million as of June 30, 2022 (June 30, 2021: DKK 1,282.9 million / USD 205.0 million).

Posted In: ZEAL